Entero Therapeutics amends rescission agreement adding accredited investor reps from ImmunogenX shareholders

GridAI Technologies Corp.

Amendment adds Section 5(f) to Rescission Agreement, requiring each shareholder to be an accredited investor under Rule 501 of Regulation D.
Shareholders also represent they have no need for liquidity, have evaluated investment risks, and are acquiring Membership Units for own account.
Amendment effective July 15, 2025; parties include Entero Therapeutics, ImmunogenX LLC, and former ImmunogenX shareholders.
Original Rescission Agreement, disclosed March 25, 2025, unwound the merger between Entero and ImmunogenX.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.